These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 23900581)

  • 1. Modulation of the response of prostate cancer cell lines to cisplatin treatment using small interfering RNA.
    Parra E; Ferreira J
    Oncol Rep; 2013 Oct; 30(4):1936-42. PubMed ID: 23900581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of JNK-1 by small interfering RNA induces apoptotic signaling in PC-3 prostate cancer cells.
    Parra E
    Int J Mol Med; 2012 Oct; 30(4):923-30. PubMed ID: 22766602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term activation of SAPK/JNK, p38 kinase and fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance.
    Brozovic A; Fritz G; Christmann M; Zisowsky J; Jaehde U; Osmak M; Kaina B
    Int J Cancer; 2004 Dec; 112(6):974-85. PubMed ID: 15386344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway.
    Lafarge S; Sylvain V; Ferrara M; Bignon YJ
    Oncogene; 2001 Oct; 20(45):6597-606. PubMed ID: 11641785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the phosphatase PP4 in the activation of JNK-1 in prostate carcinoma cell lines PC-3 and LNCaP resulting in increased AP-1 and EGR-1 activity.
    Inostroza J; Sáenz L; Calaf G; Cabello G; Parra E
    Biol Res; 2005; 38(2-3):163-78. PubMed ID: 16238095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of EGR-1 modulates the activity of NF-κB and AP-1 in prostate carcinoma PC-3 and LNCaP cell lines.
    Parra E; Ferreira J; Ortega A
    Int J Oncol; 2011 Aug; 39(2):345-52. PubMed ID: 21617851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protoapigenone, a novel flavonoid, induces apoptosis in human prostate cancer cells through activation of p38 mitogen-activated protein kinase and c-Jun NH2-terminal kinase 1/2.
    Chang HL; Wu YC; Su JH; Yeh YT; Yuan SS
    J Pharmacol Exp Ther; 2008 Jun; 325(3):841-9. PubMed ID: 18337475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of basal JNK activity by small interfering RNAs enhances cisplatin sensitivity and decreases DNA repair in T98G glioblastoma cells.
    Parra E; Gutiérrez L; Ferreira J
    Oncol Rep; 2015 Jan; 33(1):413-8. PubMed ID: 25351964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased expression of p21Waf1/Cip1 and JNK with costimulation of prostate cancer cell activation by an siRNA Egr-1 inhibitor.
    Parra E; Gutiérrez L; Ferreira J
    Oncol Rep; 2013 Aug; 30(2):911-6. PubMed ID: 23715767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JNK is required for maintaining the tumor-initiating cell-like properties of acquired chemoresistant human cancer cells.
    Liu Y; Zhang X; Wang J; Yang J; Tan WF
    Acta Pharmacol Sin; 2015 Sep; 36(9):1099-106. PubMed ID: 26235742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of mitogen-activated protein kinase cascades by differentiation-1 protein: acquired drug resistance of hormone independent prostate cancer cells.
    Lin JC; Chang SY; Hsieh DS; Lee CF; Yu DS
    J Urol; 2005 Nov; 174(5):2022-6. PubMed ID: 16217386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia-induced increases in A549/CDDP cell drug resistance are reversed by RNA interference of HIF-1α expression.
    Min L; Chen Q; He S; Liu S; Ma Y
    Mol Med Rep; 2012 Jan; 5(1):228-32. PubMed ID: 21964646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Enhanced cisplatin cytotoxicity by RNA interfering the excision repair cross-complementing 1 gene in ovarian cancer cell lines].
    Liu GY; Qu QX; Mi RR; Qi J
    Zhonghua Fu Chan Ke Za Zhi; 2006 May; 41(5):339-42. PubMed ID: 16762192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upregulation of sestrin 2 expression via JNK pathway activation contributes to autophagy induction in cancer cells.
    Zhang XY; Wu XQ; Deng R; Sun T; Feng GK; Zhu XF
    Cell Signal; 2013 Jan; 25(1):150-8. PubMed ID: 22982090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of calcium-independent phospholipase A2 activates p38 MAPK signaling pathways during cytostasis in prostate cancer cells.
    Sun B; Zhang X; Yonz C; Cummings BS
    Biochem Pharmacol; 2010 Jun; 79(12):1727-35. PubMed ID: 20171194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to docetaxel-induced apoptosis in prostate cancer cells by p38/p53/p21 signaling.
    Gan L; Wang J; Xu H; Yang X
    Prostate; 2011 Aug; 71(11):1158-66. PubMed ID: 21656826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutant human tumor suppressor p53 modulates the activation of mitogen-activated protein kinase and nuclear factor-kappaB, but not c-Jun N-terminal kinase and activated protein-1.
    Gulati AP; Yang YM; Harter D; Mukhopadhyay A; Aggarwal BB; Benzil DL; Whysner J; Albino AP; Murali R; Jhanwar-Uniyal M
    Mol Carcinog; 2006 Jan; 45(1):26-37. PubMed ID: 16267831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TNF-α-mediated NF-κB survival signaling impairment by cisplatin enhances JNK activation allowing synergistic apoptosis of renal proximal tubular cells.
    Benedetti G; Fredriksson L; Herpers B; Meerman J; van de Water B; de Graauw M
    Biochem Pharmacol; 2013 Jan; 85(2):274-86. PubMed ID: 23103562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The mitogen-activated protein kinase phosphatase vaccinia H1-related protein inhibits apoptosis in prostate cancer cells and is overexpressed in prostate cancer.
    Arnoldussen YJ; Lorenzo PI; Pretorius ME; Waehre H; Risberg B; Maelandsmo GM; Danielsen HE; Saatcioglu F
    Cancer Res; 2008 Nov; 68(22):9255-64. PubMed ID: 19010898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of Egr-1 by siRNA in prostate carcinoma cell lines is associated with decreased expression of AP-1 and NF-κB.
    Parra E; Ferreira J; Saenz L
    Int J Mol Med; 2011 Nov; 28(5):847-53. PubMed ID: 21743958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.